Merck & Co., Inc. - 31 Jan 2025 SCHEDULE 13G/A Report for Evaxion Biotech A/S American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share (EVAX)

Filing Manager
Merck & Co., Inc.
Reporting Manager
Merck & Co., Inc.
Security
Evaxion Biotech A/S American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share
Symbol
EVAX
Shares outstanding
315,652,014 shares
Disclosed Ownership
63,004,142 shares
Ownership
20%
Form type
SCHEDULE 13G/A
Filing time
03 Feb 2025, 16:15:22 UTC
Date of event
31 Jan 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Merck & Co., Inc. disclosed 20% ownership in Evaxion Biotech A/S American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share (EVAX) on 31 Jan 2025."

Quick Takeaways

  • Merck & Co., Inc. filed SCHEDULE 13G/A for Evaxion Biotech A/S American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share (EVAX).
  • Disclosed ownership: 20%.
  • Date of event: 31 Jan 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 03 Feb 2025, 16:15.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (3)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Merck & Co., Inc. 20% 63,004,142 0 63,004,142 /s/ Kelly Grez Kelly Grez/Corporate Secretary
Merck Sharp & Dohme LLC 20% 63,004,142 0 63,004,142 /s/ Jon Filderman Jon Filderman/Vice President
Merck Global Health Innovation Fund, LLC 20% 63,004,142 0 63,004,142 /s/ William Taranto William Taranto/President & General Partner

Sponsored